2026-04-01 08:04Group 1: Company Overview and Order Situation - The company has seen a significant increase in net new orders, amounting to RMB 101.6 million, representing a year-on-year growth of 20.7% [2] - The average price of new orders stabilized in 2025, with expectations for growth in 2026 [2] Group 2: Revenue Performance - Revenue from clinical trial technical services in 2025 reached RMB 32.67 billion, showing a slight increase of 2.79% year-on-year [3] - Revenue from clinical trial-related and laboratory services was RMB 34.47 billion, reflecting a year-on-year growth of 4.57% [4] Group 3: Profit Margins - The gross margin for the company's main business decreased from 33.27% in the previous year to 26.53% in 2025 [5] - The gross margin for clinical trial technical services dropped from 29.56% to 20.09%, primarily due to order cancellations and declining order prices [5] Group 4: Strategic Outlook and AI Integration - The company's core strategy focuses on advancing digitalization and intelligence, with a self-developed AI model platform now in commercial use [6] - AI is expected to significantly enhance efficiency in data management and medical writing, although it may lead to slight price reductions [6] - The company maintains a competitive advantage in core clinical trial processes due to high barriers in medical and compliance areas [7]